drugset / Trial / NCT04895423
Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood
Phase 4
Unknown
160 enrolled
National Medical Research Center for Children's Health, Russian Federation
Non-randomizedParallel-groupSingle-blindTreatment
Summary
This comparative study analyzes the efficacy and safety of treatment of children from 6 years of age suffering from moderate to severe atopic dermatitis using an inhibitor of IL4, IL13 and classical immunosuppressants.
Timeline
- Start
- 2021-11-25
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 3 mg/m2 | Oral |
| Subject | Dupilumab | Monoclonal antibody | 200 mg | Subcutaneous |
| Subject | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | Methotrexate | Small molecule | 10 mg/m2 | Subcutaneous |
| Subject | Methotrexate | Small molecule | 15 mg/m2 | Subcutaneous |
| Subject | Mycophenolate Mofetil | Small molecule | 500 mg/m2 | Oral |
| Subject | Mycophenolate Mofetil | Small molecule | 700 mg/m2 | Oral |